Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Credit: iStock
BidenAmid rising prostate cancer cases, the American Cancer Society (ACS) has revised its screening guidelines, recommending earlier testing for men at higher risk to improve early detection.
Prostate cancer is the most common cancer among men after skin cancer and the second-leading cause of cancer deaths among men in the US. An estimated 333,830 men will be diagnosed and more than 36,000 will die from the disease in 2026.
Updated for the first time since 2010, the guidelines, published in CA: A Cancer Journal for Clinicians, introduce age- and risk-based screening schedules. They aim to detect potentially aggressive cancers while limiting unnecessary tests and treatment.
Former President Joe Biden urged men to get tested for prostate cancer after the American Cancer Society changed its screening guidelines, four days after he said his own fight with the disease has been slowing him down.
"I know firsthand the toll of this disease, and I know that catching it early saves lives. So talk to your doctor, get screened, and let’s keep working to end cancer as we know it," Biden shared in a post on X.
Previously, the ACS recommended that men discuss the benefits and risks of screening with their doctors without prescribing a specific schedule.
The revised guidelines recommend prostate-specific antigen (PSA) blood tests at different intervals based on age and risk.
1. Men At Average Risk: Ages 50–69: PSA testing every two years.
2. Men At Higher Risk
Black men:
Men with an affected father, brother or son should begin screening at 45 and continue through age 69.
Men with inherited genetic risk:
Men with inherited conditions such as BRCA2 mutations, or those with a close relative carrying a high-risk mutation who have not been tested, should discuss screening with their doctor.
3. Screening After Age 70
Screening is also not recommended at any age for men in poor health who are not expected to live another 10 years.
An elevated PSA does not necessarily mean prostate cancer or an immediate need for a biopsy. The ACS considers PSA levels high at:
If elevated, the test should be repeated, preferably within two weeks to three months. If levels remain high, further evaluation may include:
These additional steps can help avoid unnecessary biopsies and reduce screening-related harms.
For men diagnosed with low-risk prostate cancer, the ACS recommends active surveillance as the initial management approach. This involves:
Treatment may be considered if monitoring shows that the cancer is becoming more aggressive.
"Early prostate cancer usually doesn't cause signs and symptoms, which is why screening is important," said Dr. William Dahut, chief scientific officer at the ACS.
When symptoms occur, they may include:
Advanced prostate cancer may cause bone pain if the disease spreads to the bones or other organs.
However, these symptoms can also indicate conditions other than cancer. Men experiencing them should consult a doctor.
Credit: iStock
India has intensified its efforts to eliminate tuberculosis (TB) through early detection, advanced diagnostics, nutritional support and community participation under the Pradhan Mantri TB Mukt Bharat Abhiyaan, launched in September 2022, the Union Health Ministry said.
Citing the WHO Global Tuberculosis Report 2026, the ministry said India recorded a 38% decline in TB mortality since 2015, outperforming the global reduction of 35%. The country also achieved a 94% treatment success rate among patients with drug-susceptible TB.
The campaign has expanded its screening efforts through intensified 100-day campaigns, including initiatives launched on December 7, 2024, and March 24, 2026.
Between December 7, 2024, and November 8, 2026, more than 25 crore people were brought under TB screening activities.
According to the ministry, the screening drive resulted in:
"The detection of nearly 15 lakh asymptomatic cases is particularly significant, demonstrating the effectiveness of proactive screening in identifying individuals who might otherwise remain undiagnosed. Early identification facilitates timely treatment and provides opportunities to reduce TB transmission and prevent severe disease," the ministry said.
The first intensified 100-day campaign was launched on December 7, 2024, across 347 high-priority districts in 33 states and Union Territories. It was subsequently expanded nationwide to strengthen early detection, particularly among vulnerable and high-risk populations.
A second intensified 100-day campaign, launched on March 24, 2026, focused on screening in 1.58 lakh high-risk villages and wards, congregate settings and vulnerable populations.
Technology And Innovation In TB Diagnosis And Care
The campaign uses chest X-rays and rapid molecular diagnostic tests to identify and diagnose TB cases. Portable AI-enabled digital X-rays and other technology-enabled tools have also been deployed to strengthen screening and diagnosis.
The campaign focuses on prompt treatment initiation, differentiated patient care, nutritional assistance and continued community-based support to improve treatment outcomes.
Through the Ni-kshay Poshan Yojana, eligible patients receive financial assistance towards their nutritional requirements during treatment. The Ni-kshay Mitra initiative encourages individuals, institutions and organisations to provide nutritional and psychosocial support.
The ministry said 67,933 panchayats were declared TB-free in 2025, reflecting efforts to involve communities in India's TB elimination programme.
According to the WHO Global Tuberculosis Report 2026, India's estimated TB mortality rate declined from 28 per lakh population in 2015 to 18 per lakh in 2025, representing a 38% reduction.
The country also recorded a 94% treatment success rate among patients with drug-susceptible TB.
The government said 96% of the TB programme's funding requirements are being met through domestic resources.
Credit: iStock
Several viral social media trends promoting physical appearance and self-improvement have raised health concerns, with some encouraging potentially dangerous practices.
One such trend, known as "heightmaxxing", has prompted warnings from doctors after reports emerged of teenage boys taking black-market cancer drugs in an attempt to grow taller.
Aolescents are reportedly experimenting with erdafitinib, often referred to online as "ERDA" or "Erta", a prescription drug approved to treat advanced bladder cancer. The trend appears to have gained traction following online discussions suggesting the medication could increase height.
"It's extremely concerning that teenagers are experimenting with powerful cancer medications in an attempt to grow taller," Dr. Stephanie Widmer, a New York City-based emergency medicine physician, told Fox News.
"These drugs were developed to treat serious medical conditions, not to enhance physical appearance, and taking them without a legitimate medical indication or physician supervision can have devastating consequences," Widmer added.
In a statement to magazine Rolling Stone, drugmaker Johnson & Johnson emphasised that erdafitinib has never been approved to stimulate height growth and that its safety and effectiveness have not been established in children or adolescents.
Also read: After Ferritin Face, Doctors Warn About 'Ferritin Hair': What Are The Signs?
Medical research has documented unexpected growth spurts in children receiving erdafitinib for brain tumours. A 2024 study published in Hormone Research in Paediatrics described accelerated growth in two paediatric patients.
A separate case report documented a teenager who grew more than five inches during treatment but also developed serious skeletal complications.
However, doctors caution that these unexpected growth spurts do not necessarily indicate healthy skeletal development.
Dr. Jessica Gray, a family physician in Lubbock, Texas, warned that rapid, drug-induced growth could trigger dangerous structural problems, including premature growth plate damage and bone fractures, Fox News reported.
Widmer noted that height is largely determined by genetics and that there are no shortcuts to increasing it. Once the growth plates close towards the end of puberty, medications cannot reopen them. This means older adolescents taking erdafitinib could face serious health risks without any prospect of gaining height, she said.
"One of the biggest concerns is that these medications can cause serious side effects, including potentially permanent vision damage, elevated phosphate levels and other metabolic abnormalities," Widmer said.
"We're talking about adolescents whose bodies are still developing, and exposing them to these risks for a cosmetic goal is particularly troubling."
Erdafitinib works by blocking specific cellular signalling pathways involved in cancer cell growth. These pathways also play a role in bone development, which may help explain the unexpected growth observed in some paediatric patients.
Other reported side effects include skeletal pain, particularly in the hips or knees, mouth sores, loose nails and skin disorders.
Doctors advise parents to watch for unusual joint pain or unexplained physical changes and speak openly with their children if they suspect they are using medications obtained online.
Teenagers concerned about their height or growth should consult a paediatrician rather than experiment with prescription drugs.
"We should be encouraging teenagers to prioritize their health, not teaching them to gamble with it," Widmer said. "No amount of additional height is worth risking permanent damage to your vision or other serious and potentially unknown medical complications."
© $2026 Times Horizon Private Limited